Aktis Oncology Inc. (AKTS), a clinical-stage oncology company, is scheduled to present clinical imaging and dosimetry data for AKY-2519, a miniprotein radioconjugate targeting solid tumors in metastatic prostate cancer, at the 2026 annual meeting of the American Society of Clinical Oncology (ASCO) on May 30, 2026.
AKY-2519 is a novel, miniprotein radioconjugate targeting B7-H3 in solid tumors, including those in prostate and lung cancers. It contains the Actinium-225 (225Ac) alpha-emitting radioisotope that targets specific expressing tumors, facilitating anti-tumor activity by increasing penetration, internalization, and retention in cancer cells.
The data to be presented will include the normal tissue biodistribution and tumor uptake assessments of AKY-2519, evaluated through PET/CT imaging, and tumor dosimetry analyses by sequential SPECT/CT imaging. The imaging to determine the action of AKY-2519 was conducted in Germany and South Africa, on patients with metastatic castration-resistant prostate cancer (mCRPC).
The U.S. Food and Drug Administration (FDA) cleared the investigational new drug (IND) application for AKY-2519 in March, and the company plans to begin a Phase 1b trial by mid-2026.
AKTS closed Tuesday at $20.50, down 1.58%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.